Back to Newsroom

Alder BioPharmaceuticals Announces Addition to NASDAQ Biotechnology Index

BOTHELL, Wash., December 16, 2014 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, announced today that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.

Click here to read more